An exploratory, open-label, investigator-initiated study of interleukin-17A (IL-17A) blockade in patients with moderate to severe papulopustular rosacea.

An exploratory, open-label, investigator-initiated study of interleukin-17A (IL-17A) blockade in patients with moderate to severe papulopustular rosacea. Br J Dermatol. 2020 May 04;: Authors: Kumar AM, Chiou AS, Shih YH, Li S, Chang ALS Abstract Currently, few systemic medications are effective for rosacea.1 Recent research has shown elevation of interleukin (IL)-17A in rosacea.2,3 To assess if the IL-17A inhibitor,4, 5 secukinumab, could improve moderate to severe papulopustular rosacea (PPR), an exploratory, open-label, single-arm investigator initiated clinical trial in adults with moderate to severe PPR was performed after Stanford Human Subjects Panel approval. PMID: 32364247 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32364247?dopt=Abstract

Source: The British Journal of Dermatology - May 3, 2020 Category: Dermatology Authors: Kumar AM, Chiou AS, Shih YH, Li S, Chang ALS Tags: Br J Dermatol Source Type: research